Why neoantigen cancer vaccines are not conventional vaccines and cannot be mass-produced the same way
Personalized neoantigen vaccines turn mutations from an individual patient’s tumor into a custom immunotherapy, requiring sequencing, computational prediction and manufacturing to occur within the treatment window.